

**The Board of Directors' of NeuroVive Pharmaceutical AB (publ), reg. no. 556595-6538, (the "Company") resolution, subject to approval by General Meeting, to issue shares and warrants (units) with preferential rights for existing shareholders (item 7)**

---

The Board of Directors resolves, subject to approval by General Meeting, to increase the Company's share capital by not more than SEK 1,962,232.20 by an issue of not more than 39,244,644 shares, and to issue not more than 9,811,161 warrants of series 2018:1 entitling to subscription of a total of 9,811,161 shares in the Company, whereby the Company's share capital may increase by not more than SEK 490,558.05 upon exercise of the issued warrants of series 2018:1.

The issues shall be considered as one resolution and be conducted through issuance of so called units to existing shareholders with preferential rights on the terms and conditions set out below ("**Rights issue**").

1. The right to subscribe for units in the Rights issue shall apply to persons whom on the record date for the Rights issue are registered as shareholders in the Company. Each shareholder has preferential right to subscribe for units in relation to the number of shares previously held by the shareholder.
2. One (1) existing share entitles to three (3) unit rights. Sixteen (16) unit rights entitle to subscription of one (1) unit, consisting of four (4) new shares and one (1) warrant of series 2018:1.
3. The subscription price per unit is SEK 8, corresponding to a subscription price of SEK 2 per share. The warrants are issued without consideration.
4. In the event not all units are subscribed for with unit rights the Board of Directors shall, within the limit of the maximum amount of the Rights issue, resolve on allocation of units that are not subscribed for with preferential rights. Such allocation shall firstly be made to subscribers that have subscribed for units with unit rights, irrespectively of whether they were shareholders at the record date or not, and, should the Rights issue be oversubscribed, in relation to the number of units such person have already subscribed for in the Rights issue and, if this cannot be made, by drawing of lots. Secondly, allocation shall be made to others whom have subscribed for units without unit rights and, should the Rights issue be oversubscribed, in relation to the number of units that such persons has applied to subscribe for and, if this cannot be made, by drawing of lots. Thirdly, allocation shall be made to guarantors pro rata in relation to guaranteed amount.
5. The record date for deciding which shareholders who are entitled to subscribe for units with preferential rights shall be Thursday 5 April 2018.
6. Subscription of units with unit rights shall be made through payment in cash during the period from and including 10 April 2018 up to and including 24 April 2018.

7. Subscription of units without unit rights shall be made during the period stated in item 6 above. Such subscriptions shall be made on a separate subscription list. Payment for units subscribed without preferential rights shall be made in cash not later than three (3) banking days after the contract notes evidencing the allocation of units has been sent out. The Board of Directors shall have the right to extend the subscription and payment period.
8. Subscription as concerned possible subscriptions made by guarantors shall be made on a separate subscription list no later than five (5) banking days after the end of the subscription period. Payment for such subscribed and allocated units shall be made in cash no later than three (3) banking days after the contract notes evidencing the allocation of units has been sent out. The Board of Directors shall have the right to extend the subscription and payment period.
9. The new shares shall entitle to dividend for the first time on the first record date for dividend that take place after the Rights issue has been registered with the Swedish Companies Registration Office and the shares have been recorded in the share register kept by Euroclear Sweden AB. The new shares issued by subscription of warrants of series 2018:1 shall entitle to dividend for the first time on the record date for dividend that take place after the new shares have been registered with the Swedish Companies Registration Office and been recorded in the share register kept by Euroclear Sweden AB.
10. One (1) warrant of series 2018:1 entitles the holder to subscribe for one (1) new share in the Company and the subscription price shall be SEK 3.80.
11. Subscription of shares in the Company with warrants of series 2018:1 shall take place during the period from and including 1 November 2018 up to and including 30 November 2018.
12. The complete terms and conditions for warrants of series 2018:1 is attached Appendix A.

---

Documents in accordance with Chapter 13, Section 6 and Chapter 14, Section 8 in the Swedish Companies Act are attached, Appendix 1-3.

A resolution to approve the Board of Directors' resolution shall be conditional upon the Extraordinary General Meeting's resolution to amend the articles of association in accordance with item 6.

The CEO, or any other person appointed by the Board of Directors, shall have the right to make such minor adjustments that may be required in order to register the resolution with the Swedish Companies Registration Office and Euroclear Sweden AB.

---

Lund in February 2018

**NeuroVive Pharmaceutical AB (publ)**

*The Board of Directors*